105,895 Shares in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Bought by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC acquired a new stake in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 105,895 shares of the medical device company’s stock, valued at approximately $3,132,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TNDM. SG Americas Securities LLC boosted its position in Tandem Diabetes Care by 70.9% in the 3rd quarter. SG Americas Securities LLC now owns 23,510 shares of the medical device company’s stock valued at $488,000 after buying an additional 9,751 shares during the last quarter. Commonwealth Equity Services LLC boosted its position in Tandem Diabetes Care by 10.1% in the 3rd quarter. Commonwealth Equity Services LLC now owns 9,870 shares of the medical device company’s stock valued at $205,000 after buying an additional 908 shares during the last quarter. Raymond James & Associates boosted its position in Tandem Diabetes Care by 1.9% in the 3rd quarter. Raymond James & Associates now owns 40,264 shares of the medical device company’s stock valued at $836,000 after buying an additional 737 shares during the last quarter. JB Capital LLC boosted its position in Tandem Diabetes Care by 63.1% in the 3rd quarter. JB Capital LLC now owns 16,252 shares of the medical device company’s stock valued at $338,000 after buying an additional 6,288 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Tandem Diabetes Care by 18.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,506 shares of the medical device company’s stock valued at $281,000 after buying an additional 2,103 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on TNDM shares. StockNews.com raised shares of Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Friday, April 19th. Wells Fargo & Company raised shares of Tandem Diabetes Care from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $21.00 to $45.00 in a research report on Monday, April 29th. Piper Sandler reaffirmed an “overweight” rating and set a $50.00 price target (up previously from $35.00) on shares of Tandem Diabetes Care in a research report on Friday. Citigroup increased their price target on shares of Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. Finally, Stifel Nicolaus increased their price target on shares of Tandem Diabetes Care from $37.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, April 23rd. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $43.80.

Tandem Diabetes Care Stock Performance

TNDM traded down $1.22 on Monday, hitting $43.50. 1,498,367 shares of the company’s stock were exchanged, compared to its average volume of 1,770,159. The firm has a market cap of $2.81 billion, a PE ratio of -20.05 and a beta of 1.10. Tandem Diabetes Care, Inc. has a twelve month low of $13.82 and a twelve month high of $47.00. The stock has a fifty day moving average of $32.58 and a two-hundred day moving average of $26.35. The company has a current ratio of 3.81, a quick ratio of 3.01 and a debt-to-equity ratio of 1.43.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its quarterly earnings results on Wednesday, February 21st. The medical device company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Tandem Diabetes Care had a negative net margin of 18.37% and a negative return on equity of 34.38%. The firm had revenue of $196.80 million during the quarter, compared to analyst estimates of $204.86 million. On average, research analysts anticipate that Tandem Diabetes Care, Inc. will post -1.62 earnings per share for the current fiscal year.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.